BioSpace News Archive

CAR-T Cell Therapy Market: Rising Geriatric Population with Weakening Immune System Boost Market Growth

Cancer is one of the leading causes of fatalities worldwide. Chimeric antigen receptor or CAR-T cell therapy comprises re-engineering of WBC or the white blood cells of the cancer-affected patient.

June 5, 2020
·
4 min read
Glucose Monitoring Market - Demand for Better Glucose Monitoring Devices During the Pandemic of COVID-19 to Boost the Growth of Market

As a per a recent report added in the vast library of TMR Research the global glucose monitoring market is expected to witness a substantial growth during the tenure of 2019 to 2029.

June 5, 2020
·
3 min read
Deals

Calliditas Therapeutics Prices its Initial Public Offering on The Nasdaq Global Select Market in the United States

Calliditas Therapeutics AB announced the pricing of its initial public offering on The Nasdaq Global Select Market by way of a capital increase of 9,230,770 new common shares, consisting of a public offering of 8,306,770 common shares in the form of American Depositary Shares...

June 5, 2020
·
11 min read
Business

After More Than 30 Years of Service, Management Board Member Caroll H. Neubauer Retires from B. Braun

The Supervisory Board of B. Braun SE announced that Caroll H. Neubauer will retire at the end of August 2020 after thirty-two years of distinguished service to B. Braun, including twenty-nine years serving on the Management Board of the B. Braun Group.

June 5, 2020
·
3 min read
Policy

BAYLX,INC. Announces US FDA Clearance of IND Application for Its Umbilical Cord Tissue Mesenchymal Stem Cells Product to Initiate Clinical Trial in Rheumatoid Arthritis

Baylx, Inc. announced that the U.S. Food and Drug Administration has cleared Baylx’s Investigational New Drug application for BX-U001, a fresh, non-frozen human umbilical cord tissue mesenchymal stem cells product in patients with Rheumatoid Arthritis.

June 5, 2020
·
2 min read
Deals

Atlas Venture Announces $400 Million Fund XII and Expansion of Partnership

Atlas Venture, a leading early stage venture capital firm investing in groundbreaking biotech innovation, announced the closing of its twelfth fund, raising $400 million in a highly oversubscribed fundraise.

June 5, 2020
·
2 min read